AlphaTON Capital (ATON) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
18 Mar, 2026Executive summary
Transitioned from a clinical-stage biotech to a digital asset and technology company focused on the Telegram ecosystem and TON token, with significant M&A and treasury activities.
Raised $36.2M in September 2025 via private placement, including cash, stablecoins, and digital assets, to establish a TON-focused treasury.
Discontinued legacy immuno-oncology trials to preserve cash and shifted strategic focus to digital assets and Telegram-based applications.
Financial highlights
Net loss of $11.1M for the six months ended September 30, 2025, compared to $3.0M loss in the prior year period.
Cash and cash equivalents decreased to $0.2M as of September 30, 2025, from $1.7M at March 31, 2025.
Digital assets (TON and Bitcoin) valued at $1.8M and stablecoins at $3.1M as of September 30, 2025.
Raised $3.3M in cash and $32.9M in digital assets/stablecoins from September 2025 private placement.
Share-based compensation expense totaled $1.0M for the six months ended September 30, 2025.
Outlook and guidance
Significant doubt exists about the ability to continue as a going concern due to low cash reserves and ongoing operating losses.
Actively exploring additional financing options, including ATM equity programs and asset-backed loans.
Plans to expand TON treasury, deploy GPU hardware for AI computing, and invest in Telegram-based applications.
Latest events from AlphaTON Capital
- Shelf registration targets $420.7M for TON token treasury and biotech R&D, with high risk factors.ATON
Registration Filing16 Dec 2025 - Up to $40M in securities offered to support R&D, operations, and strategic options amid financial pressures.ATON
Registration Filing16 Dec 2025 - Seeking $40M shelf offering to fund R&D and operations amid financial and Nasdaq compliance pressures.ATON
Registration Filing16 Dec 2025 - Major capital shift to TON token, 7.47M shares registered for resale, high dilution risk.ATON
Registration Filing16 Dec 2025 - Up to 189,719 shares are offered for resale as the company pivots to a TON token-focused strategy.ATON
Registration Filing16 Dec 2025 - Flexible securities offerings with digital asset options and strong governance protections.ATON
Registration Filing16 Dec 2025 - Net loss dropped sharply year-over-year as non-cash charges and operating expenses declined.ATON
Q4 202525 Jul 2025 - Net loss narrowed and costs fell as Portage Biotech explores strategic options amid trial pauses.ATON
Q2 202513 Jun 2025 - Net loss improved to $1.7M as R&D spending dropped and strategic options are being explored.ATON
Q1 202513 Jun 2025